Skip to main content
. 2004 Mar 2;90(5):955–961. doi: 10.1038/sj.bjc.6601579

Figure 4.

Figure 4

Effect of CC-5013 treatment on the CD4+ and CD8+ T-cell surface expression of CD45 isoforms. Data are expressed as percentage expression on cells’ pretreatment (baseline) and at follow-up (4–5 weeks after starting treatment). For CD4+ cells: CD45RA expression; *P=0.003. CD45RO expression; NS, P=0.105. For CD8+ cells: CD45RA expression; *P=0.049. CD45RO expression; NS, P=0.065.